Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression

Journal of Neuro-Oncology

Volumn 117, Issue 1, 2014, Pages 141-145

  Eisele, Günter ^a   Wick, Antje ^b   Eisele, Anna Carina ^a   Clément, Paul M ^c   Tonn, Jörg ^d   Tabatabai, Ghazaleh ^e   Ochsenbein, Adrian ^f   Schlegel, Uwe ^g   Neyns, Bart ^h   Krex, Dietmar ⁱ   Simon, Matthias ^j   Nikkhah, Guido ^k,o   Picard, Martin ^l   Stupp, Roger ^m   Wick, Wolfgang ^b,n   Weller, Michael ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF BERN   (Switzerland)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

ⁱ UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^j UNIVERSITY HOSPITAL BONN   (Germany)

^k UNIVERSITY OF FREIBURG   (Germany)

^l Merck Serono GmbH   (Germany)

^m UNIVERSITY OF LAUSANNE   (Switzerland)

ⁿ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^o UNIVERSITY HOSPITAL ERLANGEN   (Germany)

more..

Author keywords

Cilengitide; Glioblastoma; Integrins; MRIcro; Relapse pattern

Indexed keywords

CILENGITIDE; CORTICOSTEROID; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; GENE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; O6 METHYLGUANYL DNA METHYLTRANSFERASE GENE; OBSERVATIONAL STUDY; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PREOPERATIVE EVALUATION; PROMOTER REGION; STEREOTACTIC PROCEDURE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SNAKE VENOMS; TREATMENT OUTCOME;

EID: 84899886083     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1365-x     Document Type: Article

References (13)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987-996
2. Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R, Niclou SP (2011) Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108(9):3749-3754
3. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15(3):220-231
4. Wick W, Stupp R, Beule AC, Bromberg J, Wick A, Ernemann U, Platten M, Marosi C, Mason WP, van den Bent M, Weller M, Rorden C, Karnath HO (2008) A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology 10(6):1019-1024
5. Wick A, Dorner N, Schafer N, Hofer S, Heiland S, Schemmer D, Platten M, Weller M, Bendszus M, Wick W (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69(3):586-592
6. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28(16):2712-2718
7. Rorden C, Brett M (2000) Stereotaxic display of brain lesions. Behav Neurol 12(4):191-200
8. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W (2001) Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res 61(6):2744-2750
9. Wick W, Wick A, Schulz JB, Dichgans J, Rodemann HP, Weller M (2002) Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Res 62(6):1915-1919
10. Lamszus K, Kunkel P, Westphal M (2003) Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 88:169-177
11. Wick W, Cloughesy F, Nishikawa R, Mason W, Saran F, Henriksson R, Hilton M, Kerloeguen Y, Chinot O (2013) Tumor response based on adapted Macdonald criteria and assessment of pseudoprogression (PsPD) in the phase III AVAglio trial of bevacizumab (Bv) plus temozolomide (T) plus radiotherapy (RT) in newly diagnosed glioblastoma (GBM). J Clin Oncol 31(15 suppl):2002
12. Gilbert M, Dignam J, Won M, Blumenthal D, Vogelbaum MA, Aldape K, Colman H, Chakravarti A, Jeraj R, Armstrong T, Scott Wefel J, Brown P, Jaeckle K, Schiff D, Atkins J, Brachman DG, Werner-Wasik M, Komaki R, Sulman E, Mehta M (2013) RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). J Clin Oncol 31(18 suppl 1):1
13. 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. J Clin Oncol 31(15 suppl LBA2009)